Related Experiment Video
Updated: Oct 1, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Calycosin as a Novel PI3K Activator Reduces Inflammation and Fibrosis in Heart Failure Through AKT-IKK/STAT3 Axis
Xiaoping Wang1, Weili Li2, Yawen Zhang1
1School of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Insights
Calycosin (Cal) reduces heart failure by inhibiting inflammation and fibrosis. This natural compound activates the PI3K-AKT pathway, improving cardiac function after myocardial infarction in rats.
Area of Science:
- Cardiovascular Biology
- Pharmacology
- Molecular Medicine
Background:
- Inflammation and fibrosis are key drivers of heart failure (HF) progression.
- Calycosin (Cal), from Astragalus mongholicus, shows potential for cardiac dysfunction post-myocardial infarction (MI).
- Mechanisms of Cal's effects on MI-induced inflammation and fibrosis require clarification.
Purpose of the Study:
- To investigate Cal's role in mitigating heart failure.
- To elucidate the precise molecular mechanisms underlying Cal's cardioprotective effects.
Main Methods:
- Established rat model of myocardial infarction (MI) via left anterior descending artery ligation.
- Assessed Cal's cardioprotective effects using echocardiography and histological analysis.
- Employed RNA-sequencing for pathway and gene discovery, alongside in vitro models (H9C2 cells, cardiac fibroblasts) to confirm mechanisms.
Main Results:
- Cal significantly improved cardiac function in MI rats, evidenced by echocardiography.
- Cal downregulated inflammatory markers (p-IKKα/β, p-NFκB, TNFα) and attenuated cardiac fibrosis (collagen I & III).
- Mechanistic studies revealed Cal activates the PI3K-AKT pathway, crucial for its anti-inflammatory and anti-fibrotic actions.
Conclusions:
- Calycosin effectively inhibits inflammation and fibrosis in post-MI heart failure.
- The cardioprotective effects of Cal are mediated by the activation of the PI3K-AKT signaling pathway.
- Cal demonstrates therapeutic potential for treating heart failure resulting from myocardial infarction.
Abstract:
Aim: Inflammation and fibrosis have been shown to be critical factors in heart failure (HF) progression. Calycosin (Cal) is the major active component of Astragalus mongholicus Bunge and has been reported to have therapeutic effects on the cardiac dysfunction after myocardial infarction. However, whether Cal could ameliorate myocardial infarction (MI)-induced inflammation and fibrosis and precise mechanisms remain uncertain. The aim of this study is to explore the role of Cal in HF and to clarify the underlying mechanisms. Methods: For in vivo experiments, rats underwent left anterior descending artery ligation for heart failure model, and the cardioprotective effects of Cal were measured by echocardiographic assessment and histological examination. RNA-seq approach was applied to explore potential differential genes and pathways. For further mechanistic study, proinflammatory-conditioned media (conditioned media)-induced H9C2 cell injury model and TGFβ-stimulated cardiac fibroblast model were applied to determine the regulatory mechanisms of Cal. Results: In the in vivo experiments, echocardiography results showed that Cal significantly improved heart function. GO and reactome enrichment revealed that inflammation and fibrosis pathways are involved in the Cal-treated group. KEGG enrichment indicated that the PI3K-AKT pathway is enriched in the Cal-treated group. Further experiments proved that Cal alleviated cardiomyocyte inflammatory responses evidenced by downregulating the expressions of phosphorylated IκB kinase α/β (p-IKKα/β), phosphorylated nuclear factor kapa B (p-NFκB), and tumor necrosis factor α (TNFα). Besides, Cal effectively attenuated cardiac fibrosis through the inhibitions of expressions and depositions of collagen I and collagen III. In the in vitro experiments, the phosphatidylinositol three kinase (PI3K) inhibitor LY294002 could abrogate the anti-inflammation and antifibrosis therapeutic effects of Cal, demonstrating that the cardioprotective effects of Cal were mediated through upregulations of PI3K and serine/threonine kinase (AKT). Conclusion: Cal inhibited inflammation and fibrosis via activation of the PI3K-AKT pathway in H9C2 cells, fibroblasts, and heart failure in postacute myocardial infarction rats.
More Related Videos
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
14:18Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
Published on: October 13, 2023
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...